Oncolytic Viral Therapy for Mesothelioma

Pease, Daniel F.; Kratzke, Robert A.

doi:10.3389/fonc.2017.00179

Cited by 37 publications

(39 citation statements)

References 143 publications

(172 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The results of a phase I/IIa trial (NCT01721018) testing the intrapleural administration of HSV-1716 demonstrated virus replication, pleural Th1 cytokine response, and anti-tumor immunoglobulin production (104). The use of other viral vectors [reviewed in (105)], such as attenuated versions of vaccinia or measles virus genetically engineered to produce human thyroidal sodium iodine symporter (NIS), is being investigated in different phase I clinical trials (NCT02714374, NCT01503177).…”

Section: Oncoviral Therapiesmentioning

confidence: 99%

Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future

et al. 2020

View full text Add to dashboard Cite

Malignant pleural mesothelioma (MPM) is a rare, aggressive cancer of the pleural surface associated with asbestos exposure. The median survival of MPM patients is a mere 8-14 months, and there are few biomarkers and no cure available. It is hoped that, eventually, the incidence of MPM will drop and remain low and constant, given that most nations have banned the use of asbestos, but in the meantime, the incidence in Europe is still growing. The exact molecular mechanisms that explain the carcinogenicity of asbestos are not known. Standard therapeutic strategies for MPM include surgery, often coupled with chemotherapy and/or radiotherapy, in a small percentage of eligible patients and chemotherapy in tumors considered unresectable with or without adjuvant radiotherapy. In recent years, several new therapeutic avenues are being explored. These include angiogenesis inhibitors, synthetic lethal treatment, miRNA replacement, oncoviral therapies, and the fast-growing field of immunotherapy alone or in combination with chemotherapy. Of particular promise are the multiple options offered by immunotherapy: immune checkpoint inhibitors, tumor vaccines, and therapies taking advantage of tumor-specific antigens, such as specific therapeutic antibodies or advanced cell-based therapies exemplified by the CART cells. This review comprehensively presents both old and new therapeutic options in MPM, focusing on the results of the numerous recent and ongoing clinical trials in the field, including the latest data presented at international meetings (AACR, ASCO, and ESMO) this year, and concludes that more work has to be done in the framework of tailored therapies to identify reliable targets and novel biomarkers to impact MPM management.

show abstract

Section: Oncoviral Therapiesmentioning

confidence: 99%

Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Oncolytic viruses need also to be tumor selective, and although malignant cell-specific oncolysis naturally occurs because of the impairment of the type I interferon pathway in many tumor cells, viruses may be engineered in order to increase their selectivity. Viruses may be used also for gene therapy, thereby therapeutically changing the infected tumor cells by gene transfer (116).…”

Section: Virotherapymentioning

confidence: 99%

“…The pleural location and the peculiar pattern of growth (mostly localized), which provide access to direct intratumoral injection of virus, make MPM an ideal candidate for assessing the efficacy of oncolysis (116). The safety of virotherapy has been assessed and some clinical response have been reported (114).…”

Section: Virotherapymentioning

confidence: 99%

Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?

et al. 2020

View full text Add to dashboard Cite

Malignant pleural mesothelioma (MPM) is an uncommon but aggressive and treatment resistant neoplasm with low survival rates. In the last years we assisted to an exponential growth in the appreciation of mesothelioma pathobiology, leading several new treatments to be investigated both in the early stage of the disease and in the advanced setting. In particular, expectations are now high that immunotherapy will have a leading role in the next years. However, caution is required as results from phase II studies in MPM were often not replicated in larger, randomized, phase III trials. In this review, we describe the most promising emerging therapies for the treatment of MPM, discussing the biological rationale underlying their development as well as the issues surrounding clinical trial design and proper selection of patients for every treatment.

show abstract

“…TK encoded by VACV is essential for viral replication in normal cells. The deletion of the TK gene is an important genetic modification of oncolytic VACV [109,110] to improve its safety. Oncolytic VACV with TK deletion can replicate in tumor cells but not in normal cells.…”

Section: Improving the Safety Of Ovsmentioning

confidence: 99%

Development of oncolytic virotherapy: from genetic modification to combination therapy

et al. 2020

View full text Add to dashboard Cite

Oncolytic virotherapy (OVT) is a novel form of immunotherapy using natural or genetically modified viruses to selectively replicate in and kill malignant cells. Many genetically modified oncolytic viruses (OVs) with enhanced tumor targeting, antitumor efficacy, and safety have been generated, and some of which have been assessed in clinical trials. Combining OVT with other immunotherapies can remarkably enhance the antitumor efficacy. In this work, we review the use of wild-type viruses in OVT and the strategies for OV genetic modification. We also review and discuss the combinations of OVT with other immunotherapies.

show abstract

Oncolytic Viral Therapy for Mesothelioma

Cited by 37 publications

References 143 publications

Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future

Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future

Emerging Treatments for Malignant Pleural Mesothelioma: Where Are We Heading?

Development of oncolytic virotherapy: from genetic modification to combination therapy

Contact Info

Product

Resources

About